You're reading the free version. Trader adds the live tape and alerts.
Start tracking
AVTX Sale Disclosure
Doyle Mittie · SEC Form 4 · Filed Jun 25, 2026
Sale
Calculated transaction value
$26.1K
Doyle Mittie Chief Medical Officer
AVTX
Avalo Therapeutics
AVTX
Transaction date
Jun 23, 2026
Public filing date
Jun 25, 2026
Filing lag
Filed 2 days later
AVTX daily price context
Close on/before transaction
$17.83
Jun 23, 2026
First close after public filing
$18.2
Jun 26, 2026
30-day return after filing
+7.14%
Through Jul 27, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 1,450 shares @ $18
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001918845-26-000020
Filing cohort
Transactions in this filing
Showing 3 of 3
Trades
3
Issuers
1
Estimated value
$37.76K
Buys / sales
0 / 1
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Avalo Therapeutics, Inc. AVTX | Exercise | Jun 23, 2026 | $11.66K |
| Avalo Therapeutics, Inc. AVTX Current | Sale | Jun 23, 2026 | $26.1K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Jun 23, 2026 | $0 |